ADPTAdaptive Biotechnologies Corporation
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +43% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ADPT is trading
Adaptive Biotechnologies Corporation is +98% over the past year while the S&P 500 is +18%: 80 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +43%
vs 200-day average · a clear uptrend
- RSI (14)
- 44
RSI (14) · neutral
- Below its 52-week high
- 11%
Below its 52-week high
Details›
- Last close2026-10-09
- $26.49
- 1 monthS&P 500 +2.7%
- +9.2%
- 1 yearS&P 500 +18%
- +98%
- 5 yearsS&P 500 +88%
- −27%
- vs 50-day average$25.94
- +2.1%
- 52-week high
- $29.86
- 52-week low
- $12.41
- Annualised volatility
- 75%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$19M
| Year | Return |
|---|---|
| 2026 (year to date) | +63% |
| 2025 | +171% |
| 2024 | +22% |
| 2023 | −36% |
| 2022 | −73% |
| 2021 | −53% |
| 2020 | +98% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 3 of 7 | −0.67% |
| Feb | 7 | 3 of 7 | −3.4% |
| Mar | 7 | 1 of 7 | −11% |
| Apr | 7 | 3 of 7 | −8.4% |
| May | 7 | 4 of 7 | +10% |
| Jun | 7 | 6 of 7 | +13% |
| Jul | 8 | 4 of 8 | +1.3% |
| Aug | 8 | 5 of 8 | +7.8% |
| Sep | 8 | 4 of 8 | −3.7% |
| Oct | 8 | 2 of 8 | −3.7% |
| Nov | 7 | 5 of 7 | +4.9% |
| Dec | 7 | 5 of 7 | +3.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Diagnostics & Research
Ranks #13 of 21 by RyuScore